Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

NCT02710188 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: HTL0009936 modified release
DRUG: HTL0009936 immediate release

Sponsor

Nxera Pharma UK Limited

Collaborators

[object Object]